Abstract
Novel Approaches in Cancer Study Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Nibash Budhathoki1, Ajay Dhakal2* and Mateusz Opyrchal2 1Department of Medicine, Interfaith Medical Center, USA 2Department of Medicine, Roswell Park Cancer Institute, USA *Corresponding author: Ajay Dhakal, Clinical Fellow, Department of Medicine, Roswell Park Cancer Institute, University at Buffalo, Elm and Carlton Streets, 14263, Buffalo, New York, USA Submission: August 09, 2017; Published: August 21, 2017 DOI: 10.31031/NACS.2017.01.000501 ISSN:2637-773XVolume1 Issue1
Highlights
Immune Checkpoint Inhibitors in Triple Negative Breast CancerKeywords: Immune Checkpoint Inhibitors; Triple Negative Breast Cancer; Breast Cancer; PD1; PD-L1, Pembrolizumab; Nivolumab; Atezolizumab Abbreviations: CTLA4: Cytotoxic T Lymphocyte Antigen 4; PD1: Programmed Death 1; BMS: Bristol Myers Squibb; tumor infiltrating lymphocytes (TILs): Tumor Infiltrating Lymphocytes; triple negative breast cancer (TNBC): Triple Negative Breast Cancer; IHC: Immunohistochemistry; complete response (CR): Complete Response; partial response (PR): Partial Response; stable disease (SD): Stable Disease; progression free survival (PFS): Progression Free Survival; immune cells (IC): Immune Cells; overall response rate (ORR): Overall Response Rate; pathological complete response (pCR): Pathological Complete Response; hormone receptor (HR): Hormone Receptor
The role of immune system in treating cancer is being increasingly seen as important [1]
PD-L1 expression has been suggested as a predictive biomarker for these antibodies but due to lack of a single standardized assay for measuring the expression of these surface proteins and lack of consistency in trial design across different antibodies, data supporting the predictive value of PD-L1 expression are not uniform [18]
Summary
Keywords: Immune Checkpoint Inhibitors; Triple Negative Breast Cancer; Breast Cancer; PD1; PD-L1, Pembrolizumab; Nivolumab; Atezolizumab Abbreviations: CTLA4: Cytotoxic T Lymphocyte Antigen 4; PD1: Programmed Death 1; BMS: Bristol Myers Squibb; TIL: Tumor Infiltrating Lymphocytes; TNBC: Triple Negative Breast Cancer; IHC: Immunohistochemistry; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PFS: Progression Free Survival; IC: Immune Cells; ORR: Overall Response Rate; pCR: Pathological Complete Response; HR: Hormone Receptor
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
